The role of a new polyclonal competitive thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer with structural disease but low levels of serum thyroglobulin by immunometric and LC-MS/MS methods

• Published in: Endocrine Vol. 72; no. 3; pp. 784 - 790
• Main Authors: Guastapaglia, Leila, Kasamatsu, Teresa S., Nakabashi, Claudia Cristina D., Camacho, Cléber P., Maciel, Rui M. B., Vieira, José Gilberto H., Biscolla, Rosa Paula M.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.06.2021; Springer Nature B.V
• Subjects: Biotin; Competition; Diabetes; Endocrinology; Humanities and Social Sciences; Immunoglobulin G; Internal Medicine; Medicine; Medicine & Public Health; Metastases; Metastasis; multidisciplinary; Original Article; Polyclonal antibodies; Science; Thyroglobulin; Thyroid cancer; Thyroid carcinoma; LC-MS/MS; Thyroglobulin; Thyroglobulin antibodies and thyroid cancer; Competitive assay
• ISSN: 1355-008X; 1559-0100
• DOI: 10.1007/s12020-020-02526-8

Purpose The aims of this study were to assess the role of an in-house competitive thyroglobulin assay (Tg-c) in the follow-up of metastatic differentiated thyroid carcinoma (DTC) patients who presented underestimated Tg measurements by immunometric assays (Tg-IMA) and to compare the results with IMA and LC-MS/MS Tg methods. Methods This prospective study included 40 patients. Twenty-one with metastatic disease: 14 had Tg-IMA levels inappropriately low or undetectable (eight patients with positive and six with borderline TgAb) and seven had high Tg-IMA levels. Nineteen had an excellent response to therapy. The competitive assay employs a polyclonal antibody produced in rabbits immunized with human Tg, Tg labeled with biotin, and for the solid phase separation, a monoclonal anti-rabbit IgG antibody adsorbed to microtiter plates. Results All 14 patients with structural disease and underestimated levels of Tg-IMA presented detectable Tg-c levels. The median Tg-c level in the group with positive TgAb was 183 µg/L (range: 22–710 µg/L), and 58 µg/L (range 23–148 µg/L) in the borderline TgAb group. The levels of Tg-LC-MS/MS were detectable in some patients (range < 0.5–18 µg/L). All seven patients with high Tg-IMA presented also high levels of Tg-c. Only 2/19 patients with excellent response had Tg-c levels above the functional sensitivity. Conclusions The competitive assay was able to detect Tg in all patients, even in the presence of serum TgAb, and may be an option in patients with underestimated Tg-IMA and relevant structural disease.